Incyte Corporation: CMS Agreement Removes Opzelura Medicaid Overhang; Incremental Positive in Our View

Research evidence excerpt

Incyte Corporation: CMS Agreement Removes Opzelura Medicaid Overhang; Incremental Positive in Our View

Equity Research

U.S. Small & Mid Cap Biotechnology

22 June 2026

Incyte Corporation

CMS Agreement Removes Opzelura

Medicaid Overhang; Incremental

INCY OVERWEIGHTPositive in Our View

U.S. Small & Mid Cap POSITIVE

Favorable CMS agreement removes line extension risk for Biotechnology Price Target USD 117.00

Opzelura, driving a ~$246M one‑time benefit and supporting Price (18-Jun-26) USD 98.22

Potential Upside/Downside +19.1%structurally improved gross‑to‑net economics going forward. Source: Bloomberg, Barclays Research

Incyte disclosed via 8K this morning an agreement with CMS resolving litigation over

whether Opzelura should be treated as a “line extension” of Jakafi under Medicaid rebate Etzer Darout, PhD, MBA

rules. The agreement is favorable: Opzelura will be treated as a standalone product, +1 212 526 6940

resulting in a ~$246M one‑time 2Q26 benefit from accrual reversal and supporting a etzer.darout@barclays.com

structurally improved gross‑to‑net (GTN) profile going forward. We view this as BCI, US

incrementally positive, removing a regulatory overhang that could have weighed on the Gustave Diep, MD

long‑term economics of the Opzelura franchise. +1 212 526 0347

gustave.diep@barclays.com

What was at issue – Medicaid “line extension” designation risk BCI, US

The dispute centered on whether Opzelura would be treated as a line extension of Jakafi for

Lukas Shumway, PhD

Medicaid rebate purposes, which would have allowed CMS to apply Jakafi’s historical pricing +1 212 526 7293

baseline in calculating inflation rebates. This approach could have materially increased lukas.shumway@barclays.com

Opzelura’s rebate burden over time.